Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
Grant support
IHBT - 00023736
Ministerstvo Zdravotnictví Ceské Republiky
NU21-07-00225
Agentura Pro Zdravotnický Výzkum České Republiky
BBMRI.cz no. LM2023033
Ministerstvo Školství, Mládeže a Tělovýchovy
e-INFRACZID
Ministerstvo Školství, Mládež a Tělovýchovy
90140
Ministerstvo Školství, Mládež a Tělovýchovy
PubMed
38314531
DOI
10.1002/ajh.27232
Knihovny.cz E-resources
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Drug Resistance, Neoplasm genetics MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive * genetics MeSH
- Chronic Disease MeSH
- Protein Kinase Inhibitors pharmacology MeSH
- Humans MeSH
- Mutation MeSH
- Leukemia, Myeloid * MeSH
- High-Throughput Nucleotide Sequencing MeSH
- Check Tag
- Humans MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fusion Proteins, bcr-abl MeSH
- Protein Kinase Inhibitors MeSH
Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 Jena University Hospital Jena Germany
Institute of Hematology and Blood Transfusion Prague Czech Republic
See more in PubMed
Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS). Blood. 2010;116:3758-3765.
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966-984.
Poláková KM, Polívková V, Rulcová J, et al. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Exp Hematol. 2010;38:20-26.
Soverini S, Gnani A, De Benedittis C, et al. Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib. Leuk Res. 2011;35:1527-1529.
